**Exhibit99.1**
| Angeion Corporation        |   |
|----------------------------|--------|
| 350 Oak Grove  Parkway     |
| St. Paul, MN  55127 USA    |
| Telephone: (651)  484-4874 |
| Facsimile: (651)  484-4826 |

**FOR IMMEDIATE RELEASE**

Contact:                 RodneyA. Young, President and Chief Executive Officer, (651) 484-4874

Dale H. Johnson, ChiefFinancial Officer, (651) 484-4874

***Angeion Corporation Reports***

***Results for the Third Quarter of 2007***

Notable Sales Growth in Core Markets

**SAINT PAUL, Minnesota. (September 13, 2007)**— Angeion Corporation (NASDAQ: ANGN)today reported results for its third quarter ended July 31, 2007.

“Asanticipated, sales to our core markets showed notable year-over-year revenuegrowth.   This growth was strong enoughto offset the expected revenue-reduction from our large clinical researchcustomer, as it enters the next phase of its clinical trials which does notrequire additional cardiorespiratory diagnostic systems,” Rodney A. Young,President and Chief Executive Officer commented.  “Our third quarter performance in thehospital, physician office, clinic and health & fitness club marketsreflects the continuing strength of our sales and marketing teams and ourproduct technologies.”

**ThirdQuarter Highlights**

Notableaccomplishments for the quarter included:

·      44%revenue growth in our core markets for the third quarter of 2007; excluding ourlarge clinical research customer

·      Grossmargin improvement to 49.9% versus 49.0% in third quarter of 2006; and

·      Totalrevenue for the third quarter of 2007 increased slightly over last year, evenwith reduced clinical research revenues

Angeionreported revenues of $8.9 million in the third quarter, ended July 31, 2007, up0.8% from revenues of $8.8 million in the third quarter of last year.  The Company had net income of $4,000, or$0.00 per diluted share, in the third

1

----

quarterof 2007 versus net income of $394,000, or $0.10 per diluted share, in the thirdquarter last year.

For the ninemonths ended July 31, 2007, Angeion reported revenues of $29.4 million versus$22.9 million in the same period of last year. Net income for the first nine months of fiscal 2007 was $946,000, or$0.22 per diluted share, versus $682,000, or $0.18 per diluted share, in thesame period of last year, a gain of 38.7%. Net income for the nine months ended July 31, 2006, included a gain fromdiscontinued operations of $171,000 or $0.04 per diluted share.

The Companyreported that sales to its large clinical research customer accounted for 11.1%of sales in the third quarter of 2007 versus 37.7% in the third quarter of2006.  Excluding sales to this customer,revenue for the three months increased by $2.4 million, or 43.8%, compared tothe third quarter of 2006.  The Companyexpects revenues from this clinical research customer to continue throughoutfiscal 2008, but at a reduced level due to the completion of the systemsinstallation phase of its current clinical studies.

The Companyreported that its gross margin improved to 49.9% in the third quarter of fiscal2007, up from 49.0% in the same quarter last year, as a result of manufacturingefficiencies and improved product mix. However, operating expenses were higher, primarily as a result oftechnical service costs necessary to support the clinical research businesssecured over the past eighteen months. The Company also incurred additional costs that were one-time in nature,including establishing a new business-development branch office in Milan,Italy; fees related to establishing a new international distributor; and costsand expenses associated with a special shareholder meeting held in August 2007.

“We are excitedthat MedGraphics’ cardiorespiratory diagnostic product revenues in the thirdquarter of 2007 grew by nearly 44% over 2006, even without the significantcontribution of our large clinical research customer,” Young commented.  “In addition, New Leaf revenues grew as aresult of unit sales of Client Assessment Packs, the indicator of new consumerparticipation in the New Leaf Active Metabolic TrainingTM programs, whichincreased 66% in the third quarter compared to the same period of 2006.”

**LookingAhead**

“New products areparamount to our overall growth strategy; and our near-term plans includeseveral new product introductions,” Young said. “One of our new products will address a growing need in the hospitalintensive care unit (ICU) for precise measurement of the nutritional needs ofpatients on ventilators.  Failure to meetthe challenges associated with managing the nutritional requirements of critically-ill,ventilated-patients can lead to multiple complexities; including extendedhospital-patient stays, significantly increased hospital costs, patientmorbidity and mortalities.  In the U.S.alone, there are approximately 3,400

2

----

hospital ICUs andapproximately 84,000 ventilators in use for critically-ill patients. The newproduct we have developed to answer this market need is a small, portablemedical device, called an indirect calorimeter that will uniquely provide anutritional measurement for ventilated patients.  We anticipate revenues from this newICU-based product to begin by the end of this fiscal year,” Young stated.

“For the remainderof 2007, our focus remains on the basic business fundamentals; drive sales inour cardiorespiratory MedGraphics hospital/physician office market segment, addnew clients to our clinical research business roster, and increase the numberof new participants using our New Leaf Active Metabolic TrainingTM.  We are continuing to bring forth new productconcepts and the associated patents into our pipeline,” concluded Young.

3

----

**AboutAngeion Corporation**

Foundedin 1986, Angeion Corporation acquired Medical Graphics Corporation in December1999.  Medical Graphics develops,manufactures and markets non-invasive cardiorespiratory diagnostic systems thatare sold under the MedGraphics (www.medgraphics.com) and New Leaf(www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range ofapplications in healthcare as well as health and fitness.  The Company’s products are soldinternationally through distributors and in the United States through a directsales force that targets heart and lung specialists located in hospitals,university-based medical centers, medical clinics and physicians’ offices,pharmaceutical companies, medical device manufacturers, clinical researchorganizations, health and fitness clubs, personal training studios, and otherexercise facilities.  For moreinformation about Angeion, visit www.angeion.com.

Thediscussion above contains forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995.  These statements by their nature involvesubstantial risks and uncertainties.  Ouractual results may differ materially depending on a variety of factorsincluding: (i) our ability to successfully operate our business including ourability to develop, improve, and update our cardiorespiratory diagnosticproducts and successfully sell these products into existing and new markets, (ii)our ability to achieve constant margins for products and consistent andpredictable operating expenses in light of variable revenues from our clinicalresearch customers, (iii) our ability to effectively manufacture and shipproducts in required quantities to meet customer demands, (iv) our ability tosuccessfully defend ourselves from product liability claims related to ourcardiorespiratory diagnostic products and claims associated with our priorcardiac stimulation products, (v) our ability to protect our intellectualproperty, (vi) our ability to develop and maintain an effective system ofinternal controls and procedures and disclosure controls and procedures, and(vii) our dependence on third-party vendors.

Additional information with respect to the risks anduncertainties faced by the Company may be found in, and the above discussion isqualified in its entirety by, the other risk factors that are described fromtime to time in the Company’s Securities and Exchange Commission reports,including the Annual Report on Form 10-KSB for the year ended October 31, 2006,and subsequently filed Form 10-QSB and Form 8-K reports.

— FinancialsFollow —

4

----

**ANGEION CORPORATION ANDSUBSIDIARIES**

**Condensed ConsolidatedStatements of Earnings**

(unaudited,in thousands except per share amounts)
| ** **                                               | ** ** | **Three Months Ended** | ** ** | **Nine Months Ended** | ** ** |
|----------------------------------------------------------|------------|----------------------------------|------------|---------------------------------|------------|
| ** **                                               | ** ** | **July 31,**                | ** ** | **July 31,**               | ** ** |
| **Consolidated Statements of Earnings**   | ** ** | **2007**                         | ** ** | **2006**                        | ** ** | **2007** | ** ** | **2006** | ** ** |
| Revenues                                                 |       | $                                | 8,870      |                            | $          | 8,797 |   | $ | 29,449 |   | $ | 22,942 |   |
| Cost of goods  sold                                      |       | 4,448                            |       | 4,488                           |       | 14,714 |   | 11,575 |   |
| Gross margin                                             |       | 4,422                            |       | 4,309                           |       | 14,735 |   | 11,367 |   |
|                                                     |       |                             |       |                            |       |   |   |   |   |
| Operating  expenses:                                     |       |                             |       |                            |       |   |   |   |   |
| Selling and marketing                                    |       | 2,634                            |       | 2,013                           |       | 7,645 |   | 5,818 |   |
| General and administrative                               |       | 937                              |       | 809                             |       | 2,984 |   | 2,328 |   |
| Research and development                                 |       | 707                              |       | 633                             |       | 2,075 |   | 1,687 |   |
| Amortization of intangibles                              |       | 172                              |       | 203                             |       | 557 |   | 609 |   |
|                                                     |       | 4,450                            |       | 3,658                           |       | 13,261 |   | 10,442 |   |
| Operating income  (loss)                                 |       | (28                              | )          | 651                             |       | 1,474 |   | 925 |   |
| Interest income                                          |       | 48                               |       | 22                              |       | 131 |   | 50 |   |
| Income before  taxes                                     |       | 20                               |       | 673                             |       | 1,605 |   | 975 |   |
| Provision for taxes                                      |       | 16                               |       | 279                             |       | 659 |   | 464 |   |
|                                                     |       |                             |       |                            |       |   |   |   |   |
| Income from continuing  operations                       |       | 4                                |       | 394                             |       | 946 |   | 511 |   |
| Gain from  discontinued operations, net of taxes of $103 |       | —                           |       | —                          |       | — |   | 171 |   |
| Net income                                               |       | $                                | 4          |                            | $          | 394 |   | $ | 946 |   | $ | 682 |   |
|                                                     |       |                             |       |                            |       |   |   |   |   |
| Earnings per  share - basic                              |       |                             |       |                            |       |   |   |   |   |
| Continuing operations                                    |       | $                                | —     |                            | $          | 0.11 |   | $ | 0.24 |   | $ | 0.14 |   |
| Discontinued operations                                  |       | —                           |       | —                          |       | — |   | 0.05 |   |
| Net income per share                                     |       | $                                | —     |                            | $          | 0.11 |   | $ | 0.24 |   | $ | 0.19 |   |
| Earnings per  share - diluted                            |       |                             |       |                            |       |   |   |   |   |
| Continuing operations                                    |       | $                                | —     |                            | $          | 0.10 |   | $ | 0.22 |   | $ | 0.14 |   |
| Discontinued operations                                  |       | —                           |       | —                          |       | — |   | 0.04 |   |
| Net income per share                                     |       | $                                | —     |                            | $          | 0.10 |   | $ | 0.22 |   | $ | 0.18 |   |
| Weighted average  common shares outstanding              |       |                             |       |                            |       |   |   |   |   |
| Basic                                                    |       | 4,077                            |       | 3,626                           |       | 3,953 |   | 3,619 |   |
| Diluted                                                  |       | 4,262                            |       | 3,789                           |       | 4,263 |   | 3,755 |   |

 
| ** **                       | ** ** | ** ** | ** ** | ** ** | ** ** | **July 31** | ** ** | **October 31,** | ** ** |
|----------------------------------|------------|------------|------------|------------|------------|-------------|------------|-----------------|------------|
| **Consolidated  Balance Sheets** | ** ** | ** ** | ** ** | ** ** | ** ** | **2007**    | ** ** | **2006**        | ** ** |
| Cash                             |       |       |       |       |       | $           | 5,058      |            | $          | 4,069 |   |
| Other current  assets            |       |       |       |       |       | 14,354      |       | 12,821          |       |
| Equipment and  intangible assets |       |       |       |       |       | 4,070       |       | 4,863           |       |
|                             |       |       |       |       |       | $           | 23,482     |            | $          | 21,753 |   |
|                             |       |       |       |       |       |        |       |            |       |
| Current  liabilities             |       |       |       |       |       | 5,697       |       | 6,686           |       |
| Long-term  liabilities           |       |       |       |       |       | 769         |       | 757             |       |
| Shareholders'  equity            |       |       |       |       |       | 17,016      |       | 14,310          |       |
|                             |       |       |       |       |       | $           | 23,482     |            | $          | 21,753 |   |

 

###

5

----